
ADMA Biologics Faces Class Action Over Alleged Revenue Inflation
Investors have launched a class action lawsuit against ADMA Biologics, claiming the company masked a decline in ASCENIV sales through channel stuffing. The litigation targets public revenue projections made between August 2024 and March 2026, challenging the company’s assertion of robust 20% growth against evidence of a shrinking market share.



























